Leadership Team

Mr. Daniel Delaney is the President and Chief Executive Officer of TECHLAB. Delaney is an accomplished executive in the medical technology and diagnostics industry, with decades of operating and commercial experience.

Prior to TECHLAB, Delaney was an Operating Partner with Pharos Capital; President of Viracor-IBT Laboratories; an operator of clinical diagnostic laboratories; and he served as the Chief Operating Officer of AccuVein, a breakthrough vascular imaging company where he led the operations and commercial organization. Before Accuvein, Delaney was Senior Vice President at Alere (now Abbott Rapid Diagnostics) after having served as President of Alere North America, where he achieved success in leading growth and profitability in two major business units (Acute Care and Physicians Diagnostics). While at Alere, Delaney served on the Board of Directors of TECHLAB.

Delaney had a successful 20 year career with Abbott Laboratories, including 18 years at Abbott Diagnostics. At Abbott, he held various roles of increasing responsibility, including Business Unit Director, Infusion Therapy (Hospira and Abbott Hospital Products Division), Marketing Director, Immunoassay, and other key leadership roles within the commercial organization of Abbott Diagnostics Division.

Delaney obtained his MBA in Marketing and Finance from the City University of New York, Baruch College, Zicklin School of Business and has a Bachelor’s Degree in Business and Economics from Saint Anselm College in Manchester, New Hampshire.

Dr. David Lyerly co- founded TECHLAB in 1989 and currently serves as the Chief Science Officer.

Lyerly was a Research Scientist at Virginia Tech in the Anaerobe Lab when he and Dr. Tracy Wilkins started TECHLAB to extend their work on diagnostics for Clostridium difficile infection. He has published numerous articles on C. difficile, parasitology, and intestinal diseases on diverse areas including basic and molecular microbiology, development of diagnostic reagents for Clostridium difficile infection, protein purification, mechanism of action of toxins A and B, and possible vaccines.

Lyerly holds a bachelor’s degree from the University of North Carolina at Chapel Hill and an M.S. and Ph.D in Microbiology/Immunology from Wake Forest’s Bowman Gray School of Medicine.

Mr. Robert Day is the Chief Operating Officer at TECHLAB. He has spent 22 years in quality and operations at FDA regulated companies, including both pharmaceutical and medical devices. In his 17 years at TECHLAB, Day has assumed multiple roles of increasing responsibility in quality management and operational functions. Previously, Day worked in various management roles at Elizabeth Arden with a majority spent as microbiology lab manager.

Day has a bachelor’s degree in Biology with a concentration in microbiology and immunology from Virginia Polytechnic Institute and State University and an M.B.A. focused in project management from the Keller Graduate School of Management of DeVry University.

Mr. Greg Stanley is the Chief Commercial Officer at TECHLAB, where he is responsible for global commercial operations, including the worldwide partnership with Abbott Rapid Diagnostics.

Stanley has many years experience in the industry, having served as Vice President of Sales and Marketing for Global Diagnostics Business Unit of OPKO Health, Inc., and over 5 years as Director of Marketing and then National Director of Corporate Accounts for Roche Diagnostics. Prior to his time at Roche, Stanley had increasing scope of responsibility in sales, marketing and executive management roles at Abbott Diagnostics, Chiron Corporation, and Radiometer. He has been at the executive leadership level for almost 20 years and, during his tenure, served on the Boards of Directors for Radiometer and Oncimmune (USA) LLC.

Stanley holds a B.S. in Business Administration from the University of Missouri-Saint Louis.

Ms. Kelly Bewick is the Chief Financial Officer at TECHLAB. She is a certified public accountant (CPA) and a chartered global management accountant (CGMA) with 20 years of experience.

Bewick has performed many financial roles including CFO of General Genetics Corporation, and several corporate controller positions, including for a manufacturer of synthetic DNA called Intrexon. She also served as Director of Financial Analysis and compliance for Luna Innovations (Nasdaq: LUNA), a manufacturer of fiber optic test and measurement, sensing, and instrumentation products, and was the controller during Luna’s initial public offering.

Bewick has a B.S. in Finance from the Virginia Polytechnic Institute and State University.

Mr. Steven Harvey is Vice President of Manufacturing Operations, overseeing operations at TECHLAB’s Radford manufacturing facility. Employed by TECHLAB since 1995, Harvey is dedicated to meeting customer demands and supplying quality products on time.

Harvey serves on multiple boards throughout the area, including New River Community College, Manufacturing Technology Center, and Radford City Economic Development.

Harvey holds a Bachelor of Science from Radford University, where he majored in Biology and Chemistry and minored in Mathematics in 1995.

Dr. Joel Herbein is Vice President of Scientific Affairs at TECHLAB. He has spent 14 years with the company designing and developing in vitro diagnostics for global markets and has 26 years of experience overall. He was the Principal Investigator for eight IVDs receiving FDA, Canadian, and EU clearances or USDA licenses.

Herbein has directed multiple projects receiving a total of more than $8 million in funding from the NIH and the Bill and Melinda Gates Foundation. He has also established and maintained numerous clinical collaborations with enteric disease centers around the globe.

Herbein received a Bachelors of Science from Pennsylvania State University and a Ph.D. from Duke University under Dr. Jo Rae Wright.